Suppr超能文献

黏多糖贮积症 I 型小鼠关节疾病的特征。

Characterization of joint disease in mucopolysaccharidosis type I mice.

机构信息

Programa de pós-graduação em medicina: ciências medicas, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil.

出版信息

Int J Exp Pathol. 2013 Oct;94(5):305-11. doi: 10.1111/iep.12033. Epub 2013 Jun 21.

Abstract

Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by mutations in enzymes that degrade glycosaminoglycans (GAGs). Joint disease is present in most forms of MPS, including MPS I. This work aimed to describe the joint disease progression in the murine model of MPS I. Normal (wild-type) and MPS I mice were sacrificed at different time points (from 2 to 12 months). The knee joints were collected, and haematoxylin-eosin staining was used to evaluate the articular architecture. Safranin-O and Sirius Red staining was used to analyse the proteoglycan and collagen content. Additionally, we analysed the expression of the matrix-degrading metalloproteinases (MMPs), MMP-2 and MMP-9, using immunohistochemistry. We observed progressive joint alterations from 6 months, including the presence of synovial inflammatory infiltrate, the destruction and thickening of the cartilage extracellular matrix, as well as proteoglycan and collagen depletion. Furthermore, we observed an increase in the expression of MMP-2 and MMP-9, which could conceivably explain the degenerative changes. Our results suggest that the joint disease in MPS I mice may be caused by a degenerative process due to increase in proteases expression, leading to loss of collagen and proteoglycans. These results may guide the development of ancillary therapies for joint disease in MPS I.

摘要

黏多糖贮积症(MPS)是一种溶酶体贮积病,其特征是降解糖胺聚糖(GAG)的酶发生突变。大多数 MPS 形式都存在关节疾病,包括 MPS I。本研究旨在描述 MPS I 小鼠模型中的关节疾病进展。正常(野生型)和 MPS I 小鼠在不同时间点(从 2 个月到 12 个月)被处死。收集膝关节,进行苏木精-伊红染色以评估关节结构。番红 O 和天狼星红染色用于分析蛋白聚糖和胶原含量。此外,我们使用免疫组织化学分析基质降解金属蛋白酶(MMPs),MMP-2 和 MMP-9 的表达。我们观察到从 6 个月开始关节逐渐发生改变,包括滑膜炎症浸润、软骨细胞外基质的破坏和增厚,以及蛋白聚糖和胶原的耗竭。此外,我们观察到 MMP-2 和 MMP-9 的表达增加,这可能可以解释退行性变化。我们的结果表明,MPS I 小鼠的关节疾病可能是由于蛋白酶表达增加导致的退行性过程引起的,从而导致胶原和蛋白聚糖的丧失。这些结果可能为 MPS I 中的关节疾病的辅助治疗提供指导。

相似文献

1
Characterization of joint disease in mucopolysaccharidosis type I mice.
Int J Exp Pathol. 2013 Oct;94(5):305-11. doi: 10.1111/iep.12033. Epub 2013 Jun 21.
3
Biomechanical and histological characterization of MPS I mice femurs.
Acta Histochem. 2021 Feb;123(2):151678. doi: 10.1016/j.acthis.2020.151678. Epub 2021 Jan 9.
4
Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I.
Mol Genet Metab. 2015 Feb;114(2):146-55. doi: 10.1016/j.ymgme.2014.09.012. Epub 2014 Oct 7.
5
Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Cardiovasc Pathol. 2017 Mar-Apr;27:45-50. doi: 10.1016/j.carpath.2017.01.001. Epub 2017 Jan 6.
7
Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).
J Mol Histol. 2020 Apr;51(2):137-145. doi: 10.1007/s10735-020-09864-x. Epub 2020 Mar 11.
8
Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).
PLoS One. 2019 Dec 13;14(12):e0220429. doi: 10.1371/journal.pone.0220429. eCollection 2019.
10
Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.
Behav Brain Res. 2012 Jul 15;233(1):169-75. doi: 10.1016/j.bbr.2012.04.051. Epub 2012 May 9.

引用本文的文献

2
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.
J Inherit Metab Dis. 2025 Jan;48(1):e12816. doi: 10.1002/jimd.12816. Epub 2024 Nov 21.
3
Evaluation of tendon and ligament microstructure and mechanical properties in a canine model of mucopolysaccharidosis I.
J Orthop Res. 2024 Jul;42(7):1409-1419. doi: 10.1002/jor.25813. Epub 2024 Feb 18.
4
An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis.
Pharmaceutics. 2023 May 22;15(5):1565. doi: 10.3390/pharmaceutics15051565.
5
Proteomics identifies novel biomarkers of synovial joint disease in a canine model of mucopolysaccharidosis I.
Mol Genet Metab. 2023 Feb;138(2):107371. doi: 10.1016/j.ymgme.2023.107371. Epub 2023 Jan 4.
6
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.
Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22.
7
Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.
JIMD Rep. 2020 Dec 8;58(1):89-99. doi: 10.1002/jmd2.12190. eCollection 2021 Mar.
8
Growth Plate Pathology in the Mucopolysaccharidosis Type VI Rat Model-An Experimental and Computational Approach.
Diagnostics (Basel). 2020 May 31;10(6):360. doi: 10.3390/diagnostics10060360.

本文引用的文献

1
Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.
Behav Brain Res. 2012 Jul 15;233(1):169-75. doi: 10.1016/j.bbr.2012.04.051. Epub 2012 May 9.
2
Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.
Mol Genet Metab. 2011 Dec;104(4):608-19. doi: 10.1016/j.ymgme.2011.08.018. Epub 2011 Aug 24.
3
Basic methods in histopathology of joint tissues.
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S113-6. doi: 10.1016/j.joca.2010.05.026.
5
[Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Rev Assoc Med Bras (1992). 2010 May-Jun;56(3):271-7. doi: 10.1590/s0104-42302010000300009.
8
Mechanism of shortened bones in mucopolysaccharidosis VII.
Mol Genet Metab. 2009 Jul;97(3):202-11. doi: 10.1016/j.ymgme.2009.03.005. Epub 2009 Mar 25.
9
Characterization of metalloprotease cleavage products of human articular cartilage.
Arthritis Rheum. 2008 Aug;58(8):2420-31. doi: 10.1002/art.23654.
10
Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.
Mol Genet Metab. 2008 Jul;94(3):298-304. doi: 10.1016/j.ymgme.2008.03.018. Epub 2008 May 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验